Materiovigilance is the systematic framework for the discovery, collection, reporting, and analysis of adverse events related to medical devices, aimed at safeguarding patient health by preventing future occurrences.
Materiovigilance Programme of India (MvPI)
- Mission
Safeguard the health of Indian population by ensuring that benefits of use of medical devices are more than risks
- Vision
To improve patient safety and welfare of Indian population by monitoring adverse events related to medical devices and thereby reducing the risk associated with use of medical devices.
Ministry Of Health & Family Welfare, Government of India approved MvPI on 10th February 2015 with an effort to ensure safety of medical devices.
In January 2025, the Indian Pharmacopoeia Commission (IPC), Ghaziabad bestowed the Department of Pharmacology at AIIMS Rajkot as a medical device monitoring centre (MDMC).
The Department of Pharmacology, AIIMS Rajkot aims to contribute to the National MvPI through active monitoring, collecting the medical device adverse events (MDAEs) and reporting them to the IPC.
Co-ordinator: Dr. Rima Shah
Deputy co-ordinator: Dr. Siddhartha Dutta
Activities conducted to sensitise the healthcare workers and collect MDAEs:
- Regular hospital rounds are taken to collect MDAEs
- Educating and sensitizing the nursing officers and lab technicians to detect and report MDAEs
- Training residents to collect, assess and report MDAEs
The reporting is done by centralized indigenous software called Adverse Drug Reactions Monitoring System (ADRMS) designed for Indian Pharmacopoeia Commission.
The department is also committed to educate and keep updated through attending conferences, continued medical education sessions, webinars, training sessions and workshop on materiovigilance to ensure the safety of medical devices used as AIIMS, Rajkot.
Pharmacovigilance (PV) is the systematic process of monitoring, detecting, and preventing medication-related harm. By identifying and addressing safety concerns, PV plays a vital role in protecting patients and promoting public health.
At AIIMS, Rajkot we prioritize patient safety and well-being through our Pharmacovigilance program. Our team monitors, detects, and prevents adverse reactions associated with medications, ensuring compliance with national and international regulations.
By fostering a culture of safety and transparency, we promote the responsible use of medications and contribute to better health outcomes for our patients and the broader community.
Co-ordinator: Dr. Rima Shah
Deputy co-ordinator: Dr. Shubha Singhal